173 related articles for article (PubMed ID: 19732070)
1. Triptans: low utilization and high turnover in the general population.
Panconesi A; Pavone E; Franchini M; Mennuti N; Bartolozzi M; Guidi L; Banfi R
Cephalalgia; 2010 May; 30(5):576-81. PubMed ID: 19732070
[TBL] [Abstract][Full Text] [Related]
2. Patterns of triptans use: a study based on the records of a community pharmaceutical department.
Pavone E; Banfi R; Vaiani M; Panconesi A
Cephalalgia; 2007 Sep; 27(9):1000-4. PubMed ID: 17681022
[TBL] [Abstract][Full Text] [Related]
3. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
4. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
5. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
6. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
[TBL] [Abstract][Full Text] [Related]
7. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
8. Triptans in the Italian population: a drug utilization study and a literature review.
Panconesi A; Pavone E; Vacca F; Vaiani M; Banfi R
J Headache Pain; 2008 Apr; 9(2):71-6. PubMed ID: 18317865
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
10. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
11. Triptans--why once?
Ifergane G; Wirguin I; Shvartzman P
Headache; 2006 Sep; 46(8):1261-3. PubMed ID: 16942470
[TBL] [Abstract][Full Text] [Related]
12. Triptan use in Italy: Insights from administrative databases.
Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
[TBL] [Abstract][Full Text] [Related]
13. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
14. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial.
Søndergaard J; Foged A; Kragstrup J; Gaist D; Gram LF; Sindrup SH; Muckadell HU; Larsen BO; Herborg H; Andersen M
Scand J Prim Health Care; 2006 Mar; 24(1):16-21. PubMed ID: 16464810
[TBL] [Abstract][Full Text] [Related]
15. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
16. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
17. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
18. Incidence and determinants of migraine prophylactic medication in the Netherlands.
Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoepidemiology of triptans in a headache centre.
Ferrari A; Spaccapelo L; Sternieri E
Cephalalgia; 2010 Jul; 30(7):847-54. PubMed ID: 20647176
[TBL] [Abstract][Full Text] [Related]
20. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
